BN vs CNS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BN is the larger of the two ($84.83B market cap): the incumbent the market prices for continued execution (6.49x forward earnings, beta 1.83). CNS is the smaller challenger ($3.34B), actually pricier on forward earnings (18.42x): more room to run, but more to prove. On the numbers, BN leads on both counts: faster expected revenue growth (18% vs 1%) and a lower forward P/E (6.49x vs 18.42x). The case for CNS rests on its own driver (Interest rates and real assets): if you believe in that, CNS fits; if you believe in what the numbers show today, BN does.
BN vs CNS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BN | CNS | What it tells you |
|---|---|---|---|
| Market cap | $84.83B | $3.34B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 6.49 | 18.42 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 38.11 | 19.99 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.83 | 1.18 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 18% of range | 23% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.97 | 5.50 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BN and CNS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BN and CNS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BN and CNS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Brookfield Corporation (BN) do?
Brookfield Corporation sits at the top of the Brookfield group and reports through three pillars. Asset management runs through its roughly 73% interest in Brookfield Asset Management, whose fee-bearing capital reached a record ~$672 billion at the end of June 2026, up ~19% year over year, after record quarterly fundraising of ~$77 billion; Brookfield completed its acquisition of the rest of credit manager Oaktree in July 2026. Wealth solutions is the annuity, pension-risk-transfer and P&C insurance business (Brookfield Wealth Solutions, built from American National, Argo Group, American Equity Life and, since the 2026 acquisition, UK annuity provider Just Group) that gathers policyholder money and invests it alongside Brookfield's own funds; insurance assets reached ~$191 billion at mid-year, including ~$45 billion added by Just Group. The third pillar is the operating businesses, held partly through the listed affiliates: Brookfield Renewable (BEP/BEPC), Brookfield Infrastructure (BIP/BIPC), Brookfield Business Partners (BBU/BBUC) and a wholly owned real estate book that includes Canary Wharf, Brookfield Place and Ala Moana Center. Bruce Flatt has run the company since 2002, and the December 2022 reorganisation is what created the BN-versus-BAM split: BN kept the balance sheet and the carried interest, BAM was carved out as the pure-play, high-payout manager.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT), which in October 2026 bought the Manchester Village Shopping Center in Rock Hill, South Carolina and in November joined DLC to buy the West Street Shopping Center in Keene, New Hampshire.
BN vs CNS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BN drivers: Fee-bearing capital and carried interest at BAM; The insurance and annuity flywheel.
- CNS drivers: Interest rates and real assets; Return to organic growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The reported financials are hard to underwrite: consolidation pulls in revenue and debt from entities BN does not fully own, so ~$83 billion of trailing revenue and ~$2.3 billion of attributable net income describe the same company, and an investor has to accept management's distributable earnings framing to value it. For CNS, cNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings.
BN or CNS: which should you pick?
If the story you believe is BN's (Fee-bearing capital and carried interest at BAM), BN is the more direct way to own it; if it is CNS's (Interest rates and real assets), CNS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BN and CNS guides.
BN vs CNS: the full fundamentals
BN. At ~$38.10 the shares trade at roughly 15 times the ~$2.61 per share of distributable earnings reported for the twelve months to June, and distributable earnings per share grew a further ~16% in the third quarter, while the reported P/E near 38 is not a like-for-like multiple: depreciation on infrastructure and the share of consolidated profit belonging to outside partners both sit between revenue and attributable earnings. Brookfield's own buybacks earlier in the year averaged ~$42, above the current price, and the ten analysts in Yahoo's consensus carry a mean target near $54. Fourth quarter results are expected around February 11, 2027.
CNS. As of November 20, 2026, CNS trades at about 20 times trailing and 18.5 times forward earnings with a dividend yield near 4.1%, cheaper than in October after a further slide toward its 52-week low of about $58.39. AUM actually rose in October on market gains, so the gap between a recovering asset base and a falling share price is the current debate, alongside softer flows. The three analysts in the digest hold a mean target near $66.67 with a hold rating, close to the current price.
Headline figures (approximate, November 2026): BN shows share price / market cap ~$38.10 per share, ~$85 billion (Nov 20, 2026 close), revenue (ttm) ~$83 billion, up ~13% YoY in Q3 2026, net income attributable (ttm) ~$2.3 billion, a reported P/E near 38, distributable earnings per share (q3 2026) up ~16% year over year; CNS shows revenue (ttm) ~$600M, +11% YoY in Q3 2026, revenue (q3 2026) ~$157.4M, adjusted eps (q3 2026) ~$0.89 vs ~$0.90 consensus, net income (ttm) / net margin ~$169M / ~28%.
The bottom line: BN vs CNS
BN and CNS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BN and CNS exposure against your real portfolio. It is not an investment adviser.
Wondering how BN or CNS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Brookfield Corporation
Ask Walnut's AI anything about BN and see how it fits what you own.
FAQ
What is the difference between BN and CNS?
+
Brookfield Corporation sits at the top of the Brookfield group and reports through three pillars. Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BN or CNS the better stock?
+
Neither is universally better. BN is the larger incumbent; CNS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BN or CNS?
+
On forward P/E (as of November 2026), BN trades at 6.49x and CNS at 18.42x, so BN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BN and CNS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BN vs CNS?
+
BN: The reported financials are hard to underwrite: consolidation pulls in revenue and debt from entities BN does not fully own, so ~$83 billion of trailing revenue and ~$2.3 billion of attributable net income describe the same company, and an investor has to accept management's distributable earnings framing to value it. Leverage sits mostly at the asset level in non-recourse form (Yahoo shows ~$287 billion of consolidated debt), which limits contagion but leaves refinancing exposed to long rates and credit spreads across hundreds of separate structures. The office and retail real estate book has already required writedowns and remains the least liquid piece, though leasing improved in 2026, with net rents on expiring office leases up about 16% in the third quarter. The insurance pillar, now larger after Just Group, introduces a different risk set entirely: spread compression if rates fall, reserve assumptions on long-dated annuities, and regulators in multiple jurisdictions reviewing private-capital ownership of annuity liabilities. Integrating Oaktree adds execution risk in credit. Carried interest and realization gains depend on exit markets that shut for long stretches, and BN's ~1.8 beta means the stock has historically fallen harder than the index when sentiment turns, as the ~18% decline in 2026 shows. CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time; the AUM declines reported for August and September 2026 show that dynamic at work. EPS has come in a cent or a few cents below consensus in three of the last four quarters, and October 2026 brought net outflows of about $209 million. The dividend absorbs about 81% of trailing earnings, which leaves less cushion if profits dip. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BN or CNS; figures are approximate and dated (as of November 2026). Verify current data before investing.